Based on limited published evidence, ALG1L2 is a putative glycosyltransferase localized to the endoplasmic reticulum with predicted mannosyltransferase activity involved in glycoprotein biosynthesis. ALG1L2 was identified as one of seven glycosyltransferase genes in a prognostic glyco-risk prediction model for colorectal cancer, where it contributed to stratifying patient survival outcomes and immunotherapy response 1. Additionally, ALG1L2 copy number variation was associated with proctitis (radiation-induced rectal inflammation) in prostate cancer patients undergoing radiotherapy 2. However, the specific molecular mechanisms and biochemical functions of ALG1L2 remain largely uncharacterized.